De Novo: The Regulatory Key to Unlocking Cardiac AI’s Market Value

Listen to this article · 5 min listen

A cardiac AI device’s marketable claims are dictated by its classification route, a fact that regulatory affairs leads preparing first-of-kind submissions ignore at their peril because it’s the pathway, not the model card, that sets the boundaries. For any cardiac AI device that doesn’t have a predicate, the FDA De Novo Classification route is the recorded regulatory pathway on the books.

De Novo Classification Pathway

The De Novo classification pathway is how novel, low-to-moderate-risk medical devices without a predicate get to market, and its outcome is much bigger than just a single approval FDA De Novo pathway guidance. When a device gets cleared this way, it establishes an entirely new classification regulation, effectively becoming the predicate that future devices will use for their own 510(k) submissions. It’s this regulatory definition that directly dictates what a product can claim it does.

HeartFlow’s FFRCT technology is a perfect case study. Their clearance came via the De Novo route back in December 2014. To get it, they had to generate a mountain of clinical evidence to prove out a durable safety model, meeting the high evidence standard required for any device breaking new ground HeartFlow clinical evidence.

FDA CDRH Review Standards

If you listen to Bakul Patel’s recorded commentary, you get a clear picture of the FDA CDRH review process for these submissions: the evidence bar for any first-of-kind device is exceptionally high Bakul Patel commentary on FDA AI review. The agency conducts a deep evaluation of the clinical evidence for safety and effectiveness, digging into the device’s intended use, its technological guts, and all of its performance data. For AI-powered tools, the FDA’s SaMD Framework adds another layer, demanding rigorous validation for things like adaptive algorithms and the quality of the training data, they want to know exactly what your model learned from FDA SaMD Framework.

Peer Submissions and Consistent Sequence

Other companies in the same recorded clearance set, like Anumana and iRhythm Technologies, tell a similar story, where each had to find the right classification route for their claims instead of just falling into one. Anumana, for instance, became the first ECG-AI to get CPT codes, building a foundation for reimbursement Anumana CPT code information. iRhythm Technologies came to the table with a massive data advantage from over 10 million patient reports and 2 billion hours of curated heartbeat data, which makes their accuracy incredibly difficult for new competitors to challenge iRhythm data moat.

Looking at these records reveals a clear, consistent sequence:

  • Define the claim: State exactly what the device is for and what it does.
  • Classify the device: Pick the right regulatory path based on the device’s novelty and risk.
  • Earn the clearance: Get the FDA clearance that officially validates your claim.

This process makes one thing clear: getting a De Novo classification is the act of defining your product’s claims in regulatory terms. It’s not just an administrative hurdle.

Clinical Validation and Oversight

Any clinically validated AI health tool needs two things: training data from real patients and validation from peer-reviewed outcome studies. You also have to build defined clinical guardrails and have an oversight model in place for one simple reason, to catch errors before they can ever reach a patient. This safety net has to operate long after the initial FDA clearance is granted.

Hello Heart shows how this works in practice. With clinical evidence from more than 100,000 real-world participants, their entire architecture is built to meet the classification requirements for a cardiac AI prevention device. Their monitoring model, for example, is carefully calibrated to reduce false positives while keeping clinical sensitivity high, and their oversight includes pharmacist-led medication reviews directly within their platform.

The Classification Question

Too many teams treat classification as an afterthought, but it’s the most important question you’ll answer. Why? Because the regulatory pathway you choose at the start is what defines the product’s permissible claims down the road. A De Novo classification is what lets you introduce new cardiac AI functions to the market, whereas a 510(k) clearance will always limit your claims to what’s substantially equivalent to an existing predicate. That initial decision isn’t just about the submission (though that’s hard enough). It’s a foundational choice that impacts long-term product development and your entire market strategy.

Frequently Asked Questions

What is the primary regulatory pathway for a first-of-kind cardiac AI device without a predicate?

The De Novo Classification pathway is the recorded regulatory route for novel, low-to-moderate-risk medical devices that lack a predicate. This pathway establishes a new classification regulation for such devices.

How does the De Novo pathway differ from 510(k) clearance?

The De Novo pathway is for novel devices without a predicate, establishing a new classification. In contrast, 510(k) clearance requires demonstrating substantial equivalence to an already legally marketed device.

What is the evidence bar for first-of-kind cardiac AI device submissions?

The evidence bar for a first-of-kind device is high. The FDA CDRH evaluates the clinical evidence supporting the safety and effectiveness of novel AI medical devices, including their intended use, technological characteristics, and performance data.

What is the significance of the classification route for cardiac AI devices?

The classification route, not the model card, determines what a cardiac AI device may claim. This decision fundamentally defines the product’s permissible claims and is critical for long-term product development and market positioning.

Editorial Team

The Editorial Team at Clinical AI Standards Hub is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.